Product Description
Digoxin is used to treat heart failure and abnormal heart rhythms (arrhythmias). It helps the heart work better and it helps control your heart rate. (Sourced from: https://medlineplus.gov/druginfo/meds/a682301.html)
Mechanisms of Action: ATPase Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Algeria | Argentina | Australia | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | China | Colombia | Cyprus | Czech | Denmark | Dominican Republic | Egypt | Estonia | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Boehringer Ingelheim
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Australia, Brazil, Canada, China, France, Germany, Italy, Spain, Sweden, United States
Active Clinical Trial Count: 22
Highest Development Phases
Phase 3: Atrial Fibrillation
Phase 1: Breast Cancer|Chronic Obstructive Pulmonary Disease|Healthy Volunteers|Influenza, Human|Non-Small-Cell Lung Cancer|Oncology Solid Tumor Unspecified|Overweight|Pain Unspecified|Type 2 Diabetes
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| MAGNAM | P3 |
Recruiting |
Atrial Fibrillation |
2025-10-31 |
|
| CA127-1027 | P1 |
Not yet recruiting |
Oncology Solid Tumor Unspecified |
2025-07-31 |
|
| HRS9531-107 | P1 |
Not yet recruiting |
Type 2 Diabetes |
2025-05-01 |
|
| HDM1002-106 | P1 |
Not yet recruiting |
Overweight |
2025-02-01 |